Non-operative breast pathology: lobular neoplasia
- 1The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, UK
- 2Department of Histopathology, Addenbrooke’s Hospital, Cambridge, UK
- Dr Jorge S Reis-Filho, The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, UK; Jorge.Reis-Filho{at}icr.ac.uk
- Accepted 29 November 2006
- Published Online First 20 December 2006
Abstract
Lobular neoplasia is a relatively uncommon lesion, which is frequently diagnosed in biopsy specimens taken for other reasons. Although the histological features of this lesion are well known, its biological significance as a “risk indicator” or “breast cancer precursor” has been a matter of debate. This review provides an update on recent clinicopathological and molecular data on lobular neoplasia and how these have changed the way these lesions are perceived and, most importantly, managed. Furthermore, the current recommendations for the management of lobular neoplasia diagnosed on core needle biopsies proposed in the National Health Service Breast Cancer Screening guidelines are discussed.
- lobular carcinoma in situ
- atypical lobular hyperplasia
- E-cadherin
- pleomorphic lobular carcinoma
- β-catenin
Footnotes
-
Competing interests: None declared.
- Abbreviations:
- ADH
- atypical ductal hyperplasia
- ALH
- atypical lobular hyperplasia
- CGH
- comparative genomic hybridisation
- CNB
- core needle biopsy
- DCIS
- ductal carcinoma in situ
- ILC
- invasive lobular cancer
- LCIS
- lobular carcinoma in situ
- LN
- lobular neoplasia
